DK1687338T3 - Camelidae enkeltdomæne-antistoffer VHH, der er rettet mod epidermal vækstfaktor-receptor og anvendelser deraf - Google Patents

Camelidae enkeltdomæne-antistoffer VHH, der er rettet mod epidermal vækstfaktor-receptor og anvendelser deraf

Info

Publication number
DK1687338T3
DK1687338T3 DK03775003.1T DK03775003T DK1687338T3 DK 1687338 T3 DK1687338 T3 DK 1687338T3 DK 03775003 T DK03775003 T DK 03775003T DK 1687338 T3 DK1687338 T3 DK 1687338T3
Authority
DK
Denmark
Prior art keywords
growth factor
factor receptor
epidermal growth
domain antibodies
targeting epidermal
Prior art date
Application number
DK03775003.1T
Other languages
English (en)
Inventor
Toon Laeremans
Bergen En Henegouwen Paul P M P Van
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Application granted granted Critical
Publication of DK1687338T3 publication Critical patent/DK1687338T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK03775003.1T 2003-11-07 2003-11-07 Camelidae enkeltdomæne-antistoffer VHH, der er rettet mod epidermal vækstfaktor-receptor og anvendelser deraf DK1687338T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/BE2003/000189 WO2005044858A1 (en) 2003-11-07 2003-11-07 Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor

Publications (1)

Publication Number Publication Date
DK1687338T3 true DK1687338T3 (da) 2011-02-07

Family

ID=34558250

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03775003.1T DK1687338T3 (da) 2003-11-07 2003-11-07 Camelidae enkeltdomæne-antistoffer VHH, der er rettet mod epidermal vækstfaktor-receptor og anvendelser deraf

Country Status (9)

Country Link
US (1) US20060228355A1 (da)
EP (2) EP1687338B1 (da)
AT (1) ATE485307T1 (da)
AU (1) AU2003283136A1 (da)
DE (1) DE60334645D1 (da)
DK (1) DK1687338T3 (da)
ES (1) ES2352697T3 (da)
PT (1) PT1687338E (da)
WO (1) WO2005044858A1 (da)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
PL365999A1 (en) * 1999-05-14 2005-01-24 Imclone Systems Incorporated Treatment of refractory human tumors with epidermal growth factor receptor antagonists
EP1311291A4 (en) * 2000-08-09 2007-07-25 Imclone Systems Inc TREATMENT OF HYPERPROLIFERATIVE DISEASES USING EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
JP2005289809A (ja) * 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
WO2004015425A1 (en) 2002-08-07 2004-02-19 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
EP2267032A3 (en) * 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
NZ540194A (en) * 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
PT2316852E (pt) * 2002-11-08 2014-06-23 Ablynx Nv Anticorpos de domínio único estáveis
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
WO2005077980A2 (en) * 2004-02-13 2005-08-25 Bioceros Bv Soluble tcr-like molecules and their uses
PT1735348E (pt) * 2004-03-19 2012-07-24 Imclone Llc Anticorpo anti-receptor do factor de crescimento humano
RU2401842C2 (ru) 2004-10-08 2010-10-20 Домантис Лимитед Антагонисты и способы их применения
DE602006015281D1 (de) 2005-01-14 2010-08-19 Ablynx Nv Verfahren und testvorrichtungen zur unterscheidung verschiedener formen von krankheiten und leiden, die durch thrombocytopenia und/oder durch spontane interaktionen zwischen dem von-willebrand-faktor und plättchen gekennzeichnet sind
SI1888641T1 (sl) 2005-05-18 2012-05-31 Ablynx Nv Proteini ki vežejo serum albumin
WO2006122825A2 (en) 2005-05-20 2006-11-23 Ablynx Nv Single domain vhh antibodies against von willebrand factor
DE102005023617A1 (de) * 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
US8361462B2 (en) 2005-09-01 2013-01-29 National Research Council Of Canada Anti-apoptotic protein antibodies
WO2007042289A2 (en) * 2005-10-11 2007-04-19 Ablynx N.V. Nanobodies™ and polypeptides against egfr and igf-ir
US20100056439A1 (en) * 2005-12-06 2010-03-04 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
JP2009518025A (ja) * 2005-12-06 2009-05-07 ドマンティス リミテッド 細胞表面標的に対して結合特異性を有する二重特異性リガンドおよびその使用方法
US20110059101A9 (en) * 2006-03-13 2011-03-10 Ablynx N.V. Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling
WO2007110219A1 (en) * 2006-03-27 2007-10-04 Ablynx N.V. Medical delivery device for therapeutic proteins based on single domain antibodies
US20070269422A1 (en) * 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
CA2666511A1 (en) * 2006-10-11 2008-04-17 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and uses thereof
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
EP2727936B1 (en) 2006-11-22 2016-09-07 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
AU2007328900A1 (en) * 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
US9156914B2 (en) 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
EP2115004A2 (en) 2006-12-19 2009-11-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
CA2588106A1 (en) * 2007-05-18 2008-11-18 Nrc - Institute For Biological Sciences Single-domain antibodies and heavy chain antibody against egfr and uses thereof
EP2173772A2 (en) 2007-07-03 2010-04-14 Ablynx N.V. Providing improved immunoglobulin sequences by mutating cdr and/or fr positions
EP2183007A1 (en) * 2007-08-27 2010-05-12 Ablynx N.V. Needle-free delivery device for therapeutic proteins based on single antigen-binding domains such as nanobodies®
JP2011504740A (ja) 2007-11-27 2011-02-17 アブリンクス エン．ヴェー． ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
WO2009102421A2 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
GB2470328A (en) 2008-03-05 2010-11-17 Ablynx Nv Novel antigen binding dimer complexes, methods of making and uses thereof
AU2009235467A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Single variable domains against the Notch pathways
US8217140B2 (en) 2008-04-17 2012-07-10 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
EP2291399B1 (en) 2008-05-22 2014-06-25 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
US20110200525A1 (en) * 2008-10-09 2011-08-18 Patz Jr Edward F Vhh antibody fragments for use in the detection and treatment of cancer
CA2740561C (en) * 2008-10-14 2021-01-19 National Research Council Of Canada Bsa-specific antibodies
BRPI0919979A2 (pt) 2008-10-29 2015-12-15 Wyeth Llc formulações de moléculas de ligação de antígeno de domínio único
US10118962B2 (en) * 2008-10-29 2018-11-06 Ablynx N.V. Methods for purification of single domain antigen binding molecules
US9260508B2 (en) 2008-12-19 2016-02-16 Ablynx N.V. Method for generation of immunoglobulin sequences
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
EP2424889B1 (en) 2009-04-30 2015-08-12 Ablynx N.V. Method for the production of domain antibodies
DK2451839T3 (da) 2009-07-10 2020-07-13 Ablynx Nv Fremgangsmåde til produktion af variable domæner
LT2805731T (lt) 2009-09-03 2019-02-11 Ablynx N.V. Stabilios polipeptidų kompozicijos ir jų panaudojimas
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
US20110195494A1 (en) 2009-10-02 2011-08-11 Boehringer Ingelheim International Gmbh Dll4-binging molecules
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
AU2011212442A1 (en) 2010-02-05 2012-08-09 Ablynx Nv Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
WO2011098552A2 (en) 2010-02-11 2011-08-18 Ablynx Nv Methods and compositions for the preparation of aerosols
EA201201227A1 (ru) 2010-03-03 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Бипаратопные а-бета-связывающие полипептиды
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
MX2012012441A (es) 2010-05-04 2013-02-26 Merrimack Pharmaceuticals Inc Anticuerpos contra el receptor del factor de crecimiento epidermico (egfr) y usos de los mismos.
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
US20120225081A1 (en) 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
EP4458858A2 (en) 2010-10-29 2024-11-06 Ablynx NV Method for the production of immunoglobulin single variable domains
EP2691415B1 (en) 2011-03-28 2018-07-11 Ablynx N.V. Method for producing solid formulations comprising immunoglobulin single variable domains
US20130078247A1 (en) 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
EP3590950A1 (en) 2011-05-09 2020-01-08 Ablynx NV Method for the production of immunoglobulin single varible domains
US9505840B2 (en) 2011-05-27 2016-11-29 Ablynx N.V. Inhibition of bone resorption with RANKL binding peptides
WO2012166906A1 (en) 2011-05-31 2012-12-06 Massachusetts Institute Of Technology Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
EP2723772A1 (en) 2011-06-23 2014-04-30 Ablynx N.V. Immunoglobulin single variable domains directed against ige
AU2012311443B2 (en) 2011-09-23 2016-12-01 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
CA2850261C (en) 2011-09-30 2021-04-20 Ablynx Nv C-met immunoglobulin single variable domains
DE102011121237A1 (de) * 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa
PT2831111T (pt) 2012-03-30 2019-05-31 Boehringer Ingelheim Int Moléculas de ligação a ang2
EP2855526B1 (en) 2012-05-24 2018-11-07 VIB vzw Anti-macrophage mannose receptor immunoglobulin single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US11339208B1 (en) 2012-05-31 2022-05-24 United States Of America As Represented By The Secretary Of The Air Force Camelidae single-domain antibodies against Yersinia pestis and methods of use
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
DK2951201T3 (da) 2013-01-30 2018-01-08 Vib Vzw Hidtil ukendte kimære polypeptider til screenings- og lægemiddeldetektionsformål
DK2953973T3 (da) 2013-02-05 2019-08-12 Vib Vzw Muskarine acetylcholinreceptor-bindemidler og anvendelser deraf
JP6499090B2 (ja) 2013-03-15 2019-04-10 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ 心血管疾患において使用するための抗マクロファージマンノース受容体単一可変ドメイン
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
WO2016012363A1 (en) 2014-07-22 2016-01-28 Vib Vzw Methods to select for agents that stabilize protein complexes
JP6862343B2 (ja) 2014-12-19 2021-04-21 アブリンクス エン．ヴェー． システイン結合ナノボディダイマー
EP3294768B1 (en) 2015-05-13 2019-08-21 Ablynx N.V. T cell recruiting polypeptides based on tcr alpha/beta reactivity
WO2016180982A1 (en) 2015-05-13 2016-11-17 Ablynx N.V. T cell recruiting polypeptides based on cd3 reactivity
NO2768984T3 (da) 2015-11-12 2018-06-09
CA3132021C (en) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
JO3740B1 (ar) 2015-11-18 2021-01-31 Merck Sharp & Dohme روابط pd1/ctla4
GEP20207174B (en) 2015-11-18 2020-11-10 Merck Sharp & Dohme Ctla4 binders
JP7256011B2 (ja) 2015-11-27 2023-04-11 アブリンクス エン．ヴェー． Ｃｄ４０ｌを阻害するポリペプチド
JP2019523213A (ja) 2016-05-02 2019-08-22 アブリンクス エン．ヴェー． Ｒｓｖ感染の処置
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
JP7222888B2 (ja) 2016-11-16 2023-02-15 アブリンクス エン．ヴェー． Ｃｄ１２３及びｔｃｒアルファ／ベータに結合することが可能なｔ細胞動員ポリペプチド
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
US11964002B2 (en) 2017-02-28 2024-04-23 Vib Vzw Means and methods for oral protein delivery
JP2020519261A (ja) 2017-05-11 2020-07-02 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ 可変免疫グロブリンドメインのグリコシル化
MX2019014448A (es) 2017-06-02 2020-02-10 Merck Patent Gmbh Inmunoglobulinas de enlace a mmp13.
BR112019024333A2 (pt) 2017-06-02 2020-07-28 Merck Patent Gmbh imunoglobulinas de ligação adamts
WO2018220236A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Polypeptides binding adamts5, mmp13 and aggrecan
TW202413408A (zh) 2017-06-02 2024-04-01 比利時商艾伯林克斯公司 結合聚集蛋白聚糖之免疫球蛋白
US11155607B2 (en) 2017-07-19 2021-10-26 Vib Vzw Serum albumin binding agents
US11795235B2 (en) 2017-09-18 2023-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotoxins with albumin binding domain
EP3704160A1 (en) 2017-10-31 2020-09-09 VIB vzw Novel antigen-binding chimeric proteins and methods and uses thereof
EP3710486A1 (en) 2017-11-15 2020-09-23 Novo Nordisk A/S Factor x binders enhancing fx activation
WO2019155041A1 (en) 2018-02-12 2019-08-15 Vib Vzw Gβγ COMPLEX ANTIBODIES AND USES THEREOF
WO2019166622A1 (en) 2018-03-01 2019-09-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
CN111936516B (zh) 2018-03-19 2023-03-03 上海药明生物技术有限公司 新型抗egfr抗体多肽
EP3636657A1 (en) 2018-10-08 2020-04-15 Ablynx N.V. Chromatography-free antibody purification method
US20220276244A1 (en) 2019-04-29 2022-09-01 Confo Therapeutics N.V. Chimeric proteins and methods to screen for compounds and ligands binding to gpcrs
WO2020221888A1 (en) 2019-04-30 2020-11-05 Vib Vzw Cystic fibrosis transmembrane conductance regulator stabilizing agents
US20220220197A1 (en) 2019-05-28 2022-07-14 Vib Vzw Cancer Treatment by Targeting Plexins in the Immune Compartment
EP3976067A1 (en) 2019-05-28 2022-04-06 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
EP3799881A1 (en) 2019-10-04 2021-04-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Single domain antibodies specifically binding globo - series glycans
WO2021078786A1 (en) 2019-10-21 2021-04-29 Vib Vzw Nanodisc-specific antigen-binding chimeric proteins
MX2022005678A (es) 2019-11-11 2022-10-18 Ibi Ag Innovative Bio Insecticides Ltd Nanocuerpos para el control de insectos y usos de los mismos.
WO2021097289A1 (en) 2019-11-15 2021-05-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pegylated recombinant immunotoxins
WO2021105438A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
WO2021123360A1 (en) 2019-12-20 2021-06-24 Vib Vzw Nanobody exchange chromatography
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
KR20230012464A (ko) 2020-02-25 2023-01-26 브이아이비 브이지더블유 류신-풍부 반복 키나제 2 알로스테릭 조절제
CN113527488A (zh) 2020-04-22 2021-10-22 迈威(上海)生物科技股份有限公司 一种靶向人程序性死亡配体1（pd-l1）的单可变域抗体及其衍生物
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
US20230357424A1 (en) * 2020-08-21 2023-11-09 Synthekine, Inc. Cd45 binding molecules and methods of use
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
EP4216943A1 (en) 2020-09-24 2023-08-02 Vib Vzw Combination of p2y6 inhibitors and immune checkpoint inhibitors
MX2023003522A (es) 2020-09-25 2023-04-19 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y ox40l.
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2022129572A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
CA3206125A1 (en) 2020-12-24 2022-06-30 Vib Vzw Murine cross-reactive human ccr8 binders
CA3206124A1 (en) 2020-12-24 2022-06-30 Vib Vzw Non-blocking human ccr8 binders
EP4267617A1 (en) 2020-12-24 2023-11-01 Vib Vzw Human ccr8 binders
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
JP2024506020A (ja) 2021-02-05 2024-02-08 ブイアイビー ブイゼットダブリュ サルベコウイルス結合剤
EP4294407A1 (en) 2021-02-17 2023-12-27 Vib Vzw Inhibition of slc4a4 in the treatment of cancer
IL305318A (en) 2021-02-19 2023-10-01 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
WO2022199804A1 (en) 2021-03-24 2022-09-29 Vib Vzw Nek6 inhibition to treat als and ftd
US20240261446A1 (en) 2021-05-17 2024-08-08 Université de Liège Anti-cd38 single domain antibodies in disease monitoring and treatment
CA3225194A1 (en) 2021-06-23 2022-12-29 Vib Vzw Means and methods for selection of specific binders
CN118562006A (zh) * 2021-06-24 2024-08-30 浙江纳米抗体技术中心有限公司 人表皮生长因子受体结合分子及其应用
EP4365199A1 (en) 2021-06-29 2024-05-08 Shandong Simcere Biopharmaceutical Co., Ltd. Cd16 antibody and use thereof
CA3228014A1 (en) 2021-07-30 2023-02-16 Vib Vzm Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
AU2022320667A1 (en) 2021-07-30 2024-03-14 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-pvrig/anti-tigit bispecific antibody and application
EP4428156A1 (en) 2021-12-03 2024-09-11 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-bcma nanobody and use thereof
MX2024007564A (es) 2021-12-17 2024-07-04 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tcr\03b1\03b2, cd33 y cd123.
EP4458854A1 (en) 2021-12-31 2024-11-06 Shandong Simcere Biopharmaceutical Co., Ltd. Gprc5d antibody and application thereof
WO2023135198A1 (en) 2022-01-12 2023-07-20 Vib Vzw Human ntcp binders for therapeutic use and liver-specific targeted delivery
WO2023148397A1 (en) 2022-02-07 2023-08-10 Vib Vzw Engineered stabilizing aglycosylated fc-regions
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023222825A1 (en) 2022-05-18 2023-11-23 Vib Vzw Sarbecovirus spike s2 subunit binders
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
WO2024008904A2 (en) 2022-07-08 2024-01-11 Novo Nordisk A/S Highly potent isvd compounds capable of substituting for fviii(a)
JP7459354B2 (ja) 2022-07-08 2024-04-01 ノヴォ ノルディスク アー／エス ＦＶＩＩＩ（ａ）の代わりとなることができる非常に効力があるＩＳＶＤ化合物
WO2024068744A1 (en) 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus
WO2024105091A1 (en) 2022-11-15 2024-05-23 Imec Vzw Method and system for droplet manipulation
WO2024126805A1 (en) 2022-12-15 2024-06-20 Aarhus Universitet Synthetic activation of multimeric transmembrane receptors
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
WO2024156881A1 (en) 2023-01-27 2024-08-02 Vib Vzw CD8b-BINDING POLYPEPTIDES
WO2024156888A1 (en) 2023-01-27 2024-08-02 Vib Vzw Cd163-binding conjugates
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
US20240344078A1 (en) 2023-03-14 2024-10-17 Aarhus Universitet Genetically altered nfr5 receptor kinases
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
EP0294703B1 (en) 1987-06-10 1995-05-10 Dana-Farber Cancer Institute, Inc. Bifunctional antibody constructs and method for selectively destroying cell populations
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU664561B2 (en) 1991-06-21 1995-11-23 University Of Cincinnati, The Orally administrable therapeutic proteins and method of making
EP0603194A4 (en) 1991-07-05 1994-12-07 Seragen Inc TO THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR TARGETED MOLECULES FOR TREATING INFLAMMABLE ARTHRITIS.
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
EP1087013B1 (en) 1992-08-21 2009-01-07 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0684814B1 (en) 1993-02-22 1998-06-17 Alza Corporation Compositions for oral delivery of active agents
EP0698097B1 (en) 1993-04-29 2001-08-16 Unilever N.V. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
GB9311454D0 (en) 1993-06-03 1993-07-21 Agricultural & Food Res Pharmaceutical compositions
HU221001B1 (hu) 1994-03-17 2002-07-29 Merck Patent Gmbh. Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
CN1203178C (zh) * 1997-10-27 2005-05-25 尤尼利弗公司 多价抗原结合蛋白
DE69905291T3 (de) 1998-07-06 2009-06-25 Perkinelmer Cellular Sciences Belgium Sprl Bioluminenztest für agonisten oder antagonisten eines kalzium-gekuppelten-rezeptors
RS50273B (sr) 1998-08-18 2009-07-15 The Regents Of The Univeristy Of California, Antagonisti receptora epidermalnog faktora rasta za lečenje hipersekrecije mukusa u plućima
AU2002211658A1 (en) * 2000-10-13 2002-04-22 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
EP1332368A2 (en) * 2000-11-03 2003-08-06 Board of Regents, The University of Texas System Methods for detecting the efficacy of anticancer treatments
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
WO2003054016A2 (en) 2001-12-21 2003-07-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for cloning of variable domain sequences
AU2003248982B2 (en) * 2002-08-01 2009-12-10 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
NZ540194A (en) * 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor

Also Published As

Publication number Publication date
EP1687338A1 (en) 2006-08-09
US20060228355A1 (en) 2006-10-12
ATE485307T1 (de) 2010-11-15
ES2352697T3 (es) 2011-02-22
PT1687338E (pt) 2011-01-20
AU2003283136A1 (en) 2005-05-26
EP1687338B1 (en) 2010-10-20
DE60334645D1 (de) 2010-12-02
EP2251357A1 (en) 2010-11-17
WO2005044858A1 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
DK1687338T3 (da) Camelidae enkeltdomæne-antistoffer VHH, der er rettet mod epidermal vækstfaktor-receptor og anvendelser deraf
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
CY2018013I1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1119624T1 (el) Κρυσταλλικες μορφες του 4-μεθυλο-ν-[3-(4-μεθυλ-ιμιδαζολ-1-υλ)-5-τριφθορομεθυλο-φαινυλο] -3 -(4-πυριδιν-3-υλ-πυριμιδιν-2-υλαμινο)-βενζαμιδιου
CY1119102T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεισαυτων
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
DK1960434T3 (da) Monoklonale, humane antistoffer mod Fucosyl-GM1 og fremgangsmåder til anvendelse af anti-Fucosyl-GM1
CY1114690T1 (el) Αντισωματα αντι-nrr notch1 και μεθοδοι χρησεις αυτων
GEP20115226B (en) P-cadherin antibodies
DK2260862T3 (da) Sammensætninger og fremgangsmåder til behandling af tumorer der præsenterer survivin-antigener
DK1817301T3 (da) Forstærkere af glutamat-receptorer
ME00261B (me) Tweak vezujuća antitijela
DE602006007194D1 (de) Piezoelektrische Schwingzunge und piezoelektrisches Bauelement
CY1120206T1 (el) Μεθοδοι για τη συγκλινουσα συνθεση παραγωγων καλιχεαμικινης
NO20073368L (no) Amid-promedikament av gemcitabin, sammensetninger og anvendelse derav
ATE518887T1 (de) Anti-igsf4-antikörper und dessen verwendung